Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bulevirtide pharmacokinetics in hepatic impairment
NCT05765344Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of bulevirtide (8 arms), sponsored by Gilead Sciences. Primary endpoints: Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Day 6 and Maximum Observed Plasma Concentration at Steady State at Day 6. Started Mar 2023; status: completed.
02
Drugs
bulevirtide
Beyond the preview
Go deeper on NCT05765344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765344.